SUPAC Guidance for Pharmaceutical Industry – Complete FDA Guide to Scale-Up and Post-Approval Changes SUPAC Guidance: A Complete Guide to Scale-Up and Post-Approval Changes in the Pharmaceutical Industry The pharmaceutical industry operates under one of the most stringent regulatory frameworks in the world. After receiving FDA approval, manufacturers often need to make changes to formulations, … Read more
Types of Variation Filing in USA for Pharma: PAS, CBE-30, CBE-0 & Annual Report | Pharmashare Types of Variation Filing in USA for Pharma: PAS, CBE-30, CBE-0 & Annual Report Explained Last Updated: April 2026 | For: Regulatory Affairs, CMC, QA Professionals If you work in Regulatory Affairs for US FDA submissions, you face this … Read more
This guidance provides recommendations to sponsors of new drug applications (NDA’s), abbreviated new drug applications (ANDA’s), and abbreviated antibiotic applications (AADA’s) who intend, during the post approval period, to change: SU: Scale-up during original dossier assessment. Note that this is not SU during development. Consider changes made after the Biobatch PAC: Post-PQ/post-approval, i.e. Variations. … Read more
